Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency – final appraisal determination
DRAFT guidance recommends dostarlimab for use within the Cancer Drugs Fund as an option for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults who have had platinum-based chemotherapy.
Source:
National Institute for Health and Care Excellence
SPS commentary:
The FAD notes clinical trial evidence suggests that dostarlimab increases the time until the cancer gets worse and how long people live. However, this is uncertain because the trial is ongoing and dostarlimab has not been directly compared with other treatment options. It has the potential to be cost effective, but more long-term evidence is needed to address the clinical uncertainties. It cannot be recommended for routine use in the NHS, however it is recommended for use in the Cancer Drugs Fund so that more data can be collected.
A press release from NHS England notes that around 100 women will be offered this treatment every year.